<DOC>
	<DOCNO>NCT01561352</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial ass efficacy activate recombinant human factor VII treatment refractory haemorrhagic cystitis ( HC ) follow chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Activated Recombinant Human Factor VII Refractory Haemorrhagic Cystitis</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<criteria>Severe haemorrhagic cystitis ( HC ) Patients overt DIC ( disseminate intravascular coagulation ) Patients known active atherosclerotic disease , active coronary artery disease recent stroke past 3 month Central venous access device relate thrombus last 3 month Patients allergy activate recombinant human factor VII component preparation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>